Issues related to antimicrobial resistance and infectious disease. Issues related to public health preparedness including the SNS and supply chain. Issues related to awareness about diabetic eye diseases. Issues related to privacy and consumer information. Medical research data.
2026 · 3rd Quarter (July 1 - Sep 30)
GENENTECH, INC.
Filed by TODD STRATEGY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TODD STRATEGY GROUP
- Client
- GENENTECH, INC.
- Filing UUID
- 913abd18-4d32-470a-839d-c8fdb3d54431
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Appropriations and budget issues including: LHHS-Ed, Ag-FDA, and HHS program funding. Reconciliation and deficit reduction.
Issues related to drug pricing and coverage. Medicare and Medicaid payment issues. Implementation of the IRA. 340B Program.
Issues related to IP and patent policy reform. Issues related to FDA regulation and drug development including PDUFA and biosimilars.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.